Consistent 3-Year Sales and Profit Growth — US Stocks with Sustained Revenue and Earnings Expansion
US companies that grew both revenue and net income in each of the last 3 years — sustained top-line and bottom-line expansion across three consecutive annual periods.
About This Screen
Consistent three-year growth in both revenue and profit is the medium-term confirmation that a business's commercial momentum is real, directionally stable, and not a single-year event. Three consecutive years of both top-line and bottom-line growth means the company navigated at least three annual cycles of customer renewal decisions, competitive pressures, and macro conditions while still expanding. This consistency is far rarer than single-year growth and far more predictive of continued performance.
WHAT THIS SCREEN FINDS: US NYSE and NASDAQ stocks where both revenue and net income are higher in Year 1 (latest) than Year 2, Year 2 than Year 3, and Year 3 than Year 4 — three consecutive years of annual growth in both measures. Market cap above $500M, ROCE above 10% for quality confirmation.
KEY METRICS EXPLAINED: Three consecutive years of revenue growth confirms genuine commercial expansion, not a one-time contract spike. Three consecutive years of profit growth confirms improving or at least stable margins alongside the revenue expansion. Together, they identify businesses with the most sustained and directionally consistent financial performance available in US public equities.
WHY INVESTORS USE IT: Most quality filters look at current-period snapshots. This screen looks at three consecutive annual periods — the minimum window to identify a genuine trend versus a blip. Companies with this track record have demonstrated they can grow their business and earnings through varied conditions consistently, making them the highest-quality starting universe for fundamental research.
BENEFITS: Medium-term trend confirmation versus single-year snapshot. Both revenue AND profit required each year — prevents cost-cutting-only profit growth. ROCE quality filter adds capital efficiency confirmation. Three years captures at least one or two macro/sector events that test durability. Ideal starting universe for quality-growth investors. Strong predictor of continued quality in academic factor research.
RISKS AND LIMITATIONS: Three-year growth can end in Year 4 — past consistency doesn't guarantee future continuation. Acquisition-driven growth can create artificial three-year growth streaks. Easy prior-year comparisons can inflate apparent consistency. Always verify organic growth rates and check that revenue and profit growth are driven by the core business.
HOW TO ANALYZE STOCKS FROM THIS SCREEN: Calculate the CAGR for both revenue and profit over three years — what is the average annual growth rate? Compare growth rates across the three years — is it accelerating (Year 3 growth > Year 1 growth) or decelerating? Check for acquisition contributions. Verify ROCE trend — has it been stable or improving alongside the revenue and profit growth?
COMMON MISTAKES: Not distinguishing acquisition-driven from organic growth. Missing deceleration in the growth rate — from 20% three years ago to 5% most recently is consistent but concerning. Treating three-year consistency as a guarantee without forward earnings analysis. Not checking valuation — consistent growers often command premium multiples that reduce future return potential.
Related screens: Consistent 5-Year Earnings (longer profitability track record), Bull Cartel (quarterly momentum confirmation), Winner Stocks (strictest quality-growth screen), Coffee Can Portfolio (long-term quality compounder framework), Consistent Positive OCF (cash flow consistency alongside earnings).
Frequently Asked Questions
What does consistent 3-year sales and profit growth mean?
Both revenue and net income have grown in each of the three consecutive most recent annual periods — Year 1 above Year 2, Year 2 above Year 3, Year 3 above Year 4. This confirms three years of uninterrupted top-line and bottom-line expansion simultaneously. It's a medium-term trend confirmation that single-year screens cannot provide.
Why is three years more meaningful than one year of growth?
A single year of strong growth can reflect easy comparisons, one-time sales, or favorable macro timing. Three consecutive years of both revenue and profit growth across varied market conditions, customer renewal cycles, and competitive environments demonstrates a durable growth engine. The probability of three consecutive 'lucky years' is far lower than one fortunate year.
Which metric is more important — consistent revenue or consistent profit growth?
Both matter, and this screen requires both. Revenue growth alone could mask deteriorating margins. Profit growth alone could reflect cost-cutting that ultimately constrains revenue. Three consecutive years of both simultaneously is the strongest signal of sustainable, quality business expansion — top-line demand is real and profitable, bottom-line conversion is intact.
How does this screen differ from the Consistent 5-Year Earnings screen?
Consistent 5-Year Earnings requires positive net income (profitability) in every year but not necessarily growth. This screen requires both revenue AND profit to be higher each year — directional growth, not just profitability. The 5-year earnings screen tests durability; the 3-year growth screen tests trajectory. Combined, they identify the most consistently growing AND consistently profitable businesses.
Does acquisition activity affect this screen?
Yes — acquisitions can add revenue and profit in the year of completion, creating apparent consistent growth if timed across three years. Always check the earnings release for 'organic' or 'same-store' growth figures that exclude acquisition contributions. Three years of organic (same-store) growth is a much stronger signal than three years of acquisition-boosted reported growth.
What CAGR represents 'good' 3-year growth?
Revenue CAGR above 10% over three years is solid; above 15% is strong; above 20% is excellent. Profit CAGR above 10% is solid; above 15% is strong; above 20% with consistent revenue growth is exceptional. The direction (growth) is confirmed by the screen; the magnitude within the results determines the quality of the growth signal.
What sectors most frequently appear on this screen?
Technology (especially software and services), healthcare (pharma, medical devices, healthcare IT), consumer discretionary (expanding brands and e-commerce), and financial services (well-managed banks and insurance during expansion phases). Capital-intensive or commodity-driven sectors (energy, mining, shipping) are less likely to show three consecutive years of both metrics growing due to price cycle volatility.
How should I use this screen in combination with others?
This screen is best used as a quality confirmation step for stocks identified by other screens. A stock appearing on Magic Formula AND Consistent 3-Year Growth has both the quality-value credentials and the growth track record. A stock from Low PE High ROE AND this screen is cheap, quality, and has a growth record. Stacking multiple quality signals is the most reliable approach to high-conviction stock selection.
Can profit grow while revenue declines (and vice versa)?
Revenue can decline while profit grows only if margins expand dramatically — through cost-cutting, pricing increases, or mix shift to higher-margin products. This technically fails this screen since revenue must also grow each year. The screen specifically requires both, preventing the cost-cutting-driven profit improvement from qualifying. Genuine business quality shows in both metrics growing together.
How does this screen handle companies that had a recent acquisition?
Acquisition effects appear in all periods after the deal closes. If a company made a large acquisition in Year 3 (three years ago), the Year 2 comparison would include the acquired business, but Year 3 vs. Year 4 comparisons would not. The screen captures the reported figures — organic growth analysis requires reading the breakdown in each year's earnings release or 10-K.
Results 52 stocks matched
Refreshed daily · Sorted by Market Cap (High → Low)
| S.No. | Company | Rev Growth % | EPS Growth % | D/E | Price | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | O'Reilly Automotive, Inc. | 7.8% | 13.9% | -11.12 | $90.33 | 28.48 | $74.16 B | — | 44.58% | 423.35% | $108.72 | $85.35 |
| 2. | Fair Isaac Corporation | 16.4% | 7.7% | -1.76 | $1,137.33 | 35.18 | $26.73 B | — | 91.84% | 145.71% | $1,998.01 | $870.01 |
| 3. | TransDigm Group Incorporated | 13.9% | -12.9% | -3.1 | $1,238.74 | 33.04 | $68.8 B | 7.69% | 20.21% | 37.11% | $1,623.83 | $1,123.61 |
| 4. | Mako Mining Corp. | 74.7% | 2.1% | 0.05 | $7.35 | 15.13 | $996.49 M | — | 37.89% | 36.55% | $12.16 | $5.01 |
| 5. | Planet Fitness, Inc. | 10.7% | 32.5% | -6.01 | $50.68 | 17.64 | $4.04 B | — | 14.14% | 35.79% | $114.47 | $37.03 |
| 6. | Arista Networks, Inc. | 28.9% | 19.1% | 0.73 | $154.27 | 56.19 | $209.04 B | — | 27.4% | 30.58% | $179.8 | $85.58 |
| 7. | The Bancorp, Inc. | 2.3% | 11.9% | 0.32 | $54.11 | 9.66 | $2.23 B | — | — | 30.56% | $81.65 | $49.19 |
| 8. | Powell Industries, Inc. | 4% | 18.9% | 0.22 | $284.87 | 56.37 | $10.54 B | 0.12% | 32.88% | 28.61% | $328 | $56.7 |
| 9. | IRADIMED CORPORATION | 17% | 24.8% | 0 | $93.07 | 50.66 | $1.2 B | 0.79% | 26.52% | 24.48% | $107.9 | $55.11 |
| 10. | Zoom Communications, Inc. | 5.3% | 91.5% | 0.6 | $101.62 | 15.04 | $31.14 B | — | 11.28% | 21.79% | $114.74 | $69.15 |
| 11. | Palomar Holdings, Inc. | 62.7% | 59.9% | 0.75 | $108.51 | 14.59 | $2.88 B | — | — | 21.74% | $172.12 | $100.81 |
| 12. | United States Lime & Minerals, Inc. | 9.8% | 12.9% | 0.64 | $104.61 | 23.33 | $3.05 B | 0.22% | 24.01% | 21.28% | $141.44 | $94.02 |
| 13. | Toast, Inc. | 22% | 2.28% | 0.94 | $24.64 | 34.69 | $14.29 B | — | 13.97% | 20.74% | $49.66 | $22.26 |
| 14. | Fabrinet | 35.9% | 30.7% | 0.22 | $621.25 | 60.84 | $25.61 B | — | 16.12% | 19.74% | $748.89 | $231.51 |
| 15. | Krystal Biotech, Inc. | 17.5% | 11.6% | 0.77 | $301 | 39.43 | $8.87 B | — | 13.1% | 19.25% | $319.48 | $127.99 |
| 16. | United Therapeutics Corporation | 7.4% | 24.5% | 0.53 | $549.87 | 18.12 | $23.32 B | — | 20.73% | 19.24% | $609.35 | $272.12 |
| 17. | OR Royalties Inc. | 59.4% | 8.08% | 0.35 | $33.87 | 26.73 | $9.42 B | 0.01% | 13.19% | 18.17% | $65.54 | $33.86 |
| 18. | Unity Bancorp, Inc. | 16.1% | 23.9% | 0.77 | $55.17 | 8.9 | $539.4 M | 1.21% | — | 17.87% | $57.3 | $41.67 |
| 19. | Kanzhun Limited | 14% | 45.7% | 0.79 | $14.03 | 13.44 | $987.19 M | 0.01% | 7.76% | 17.6% | $25.26 | $12.85 |
| 20. | Intuitive Surgical, Inc. | 18.8% | 16.6% | 0.95 | $422.06 | 50.54 | $150.56 B | — | 15.96% | 16.98% | $603.88 | $396.68 |
| 21. | Copart, Inc. | -3.6% | -10% | 0.98 | $30.96 | 18.59 | $28.88 B | — | 18.04% | 16.63% | $50.92 | $29.96 |
| 22. | East West Bancorp, Inc. | 14.1% | 23.6% | 0.36 | $125.94 | 12.29 | $17.12 B | 2.56% | — | 16.06% | $127.52 | $90.32 |
| 23. | OFG Bancorp | 0% | 16.6% | 0.35 | $46.27 | 9.13 | $1.95 B | 0.03% | — | 15.62% | $46.85 | $35.71 |
| 24. | Ategrity Specialty Insurance Company Holdings | 17.9% | -9% | 0.34 | $20.34 | 10.74 | $976.98 M | 0.91% | — | 15.21% | $25.3 | $16.35 |
| 25. | BlackRock Health Sciences Trust | 7.6% | — | 0.16 | $39.94 | 6.79 | $526.14 M | 7.79% | — | 14.39% | $42.74 | $35.03 |
| 26. | BancFirst Corporation | 8.3% | 11.4% | 0.05 | $110.37 | 15.01 | $3.71 B | 1.78% | — | 13.62% | $138.77 | $101.48 |
| 27. | The Bank of New York Mellon Corporation | 13.4% | 41.8% | 0.77 | $142.39 | 15.79 | $94.14 B | 1.55% | — | 13.48% | $144.98 | $87.41 |
| 28. | 1st Source Corporation | 16.8% | 31.5% | 0.16 | $75.35 | 11.22 | $1.8 B | 2.3% | — | 12.89% | $76.44 | $56.89 |
| 29. | Third Coast Bancshares, Inc. | 20.1% | 29.2% | 0.26 | $39.21 | 9.42 | $650.58 M | 0.73% | — | 12.61% | $43.84 | $29.66 |
| 30. | Wintrust Financial Corporation | 10.3% | 19.7% | 0.62 | $152.9 | 11.58 | $9.98 B | 1.51% | — | 11.93% | $162.96 | $116.57 |
| 31. | Home BancShares, Inc. | 10.8% | 20.3% | 0.18 | $27.12 | 11.44 | $5.47 B | 3.13% | — | 11.29% | $30.83 | $25.5 |
| 32. | Byline Bancorp, Inc. | 13.8% | 29.7% | 0.39 | $33.78 | 10.99 | $1.53 B | 1.43% | — | 11.2% | $34.33 | $24.75 |
| 33. | Capital City Bank Group, Inc. | 2.2% | -7.1% | 0.13 | $45.34 | 12.63 | $764.09 M | 2.44% | — | 11.1% | $48.78 | $35.94 |
| 34. | The Descartes Systems Group Inc. | 15.1% | 21% | 0.52 | $75.46 | 41.01 | $9.32 B | — | 13.18% | 10.7% | $158.61 | $85.26 |
| 35. | SPS Commerce, Inc. | 12.7% | 46.9% | 0.74 | $55.47 | 22.2 | $2.02 B | — | 11.65% | 9.45% | $145.64 | $49.04 |
| 36. | MDA Space Ltd. | 0.2% | 1.4% | 0.3 | $38.33 | 75.19 | $5.69 B | — | 7.74% | 7.24% | $67.9 | $20.85 |
| 37. | Liberty Live Holdings, Inc. | 29% | — | -33.96 | $90.61 | 39.29 | $21.8 B | — | 660.86% | 7.17% | $99.52 | $73.7 |
| 38. | Liberty Live Holdings, Inc. | 29% | — | -33.96 | $93.35 | 39.29 | $21.8 B | — | 660.86% | 7.17% | $99.52 | $73.7 |
| 39. | Flywire Corporation | 34% | — | 0.45 | $14.4 | 58.9 | $1.78 B | — | 2.35% | 3.65% | $18.05 | $9.96 |
| 40. | DigitalOcean Holdings, Inc. | 18.3% | 90.1% | -55.84 | $169.87 | 74.86 | $17.73 B | — | 12.89% | 1.78% | $184.46 | $25.56 |
| 41. | Elemental Royalty Corporation | 1.91% | — | 0.06 | $14.93 | 600.58 | $1.52 B | 0.51% | 0.82% | -0.12% | $34.29 | $14.1 |
| 42. | Omada Health, Inc. | 58.1% | — | 0 | $17.93 | — | $1.07 B | — | -5.21% | -2.81% | $28.4 | $10.28 |
| 43. | Neptune Insurance Holdings Inc. | 38.9% | -48.4% | -1.05 | $25.49 | — | $3.53 B | 5.68% | 638.64% | -2.85% | $33.23 | $14.78 |
| 44. | Coursera, Inc. | 9.1% | — | 0.76 | $5.47 | — | $1.57 B | — | -12.19% | -10.06% | $13.56 | $5 |
| 45. | Ethos Technologies Inc. | 65.5% | 1.62% | 0.62 | $16.82 | 18.36 | $1.19 B | — | 18.13% | -28.37% | $32.5 | $9.45 |
| 46. | Esperion Therapeutics, Inc. | 1.44% | — | -0.84 | $3.13 | — | $805.76 M | — | 36.51% | -59.48% | $4.18 | $0.95 |
| 47. | Appian Corporation | 21.7% | — | -6.38 | $24.73 | 2,062.2 | $1.83 B | — | 0.25% | -140.51% | $46.06 | $18.63 |
| 48. | RingCentral, Inc. | 4.8% | — | -2.19 | $42.29 | 43.78 | $3.69 B | 0.68% | 45.87% | -231.74% | $49.85 | $23.59 |
| 49. | Guardant Health, Inc. | 39.4% | — | -17.22 | $125.61 | — | $16.66 B | — | -25.56% | -246.6% | $134.28 | $40.35 |
| 50. | Lindblad Expeditions Holdings, Inc. | 23.3% | — | -3.3 | $21.66 | — | $1.41 B | — | 8.78% | -266.5% | $23.78 | $10.46 |
| 51. | Nutanix, Inc. | 10.4% | 83.2% | -2.14 | $53.64 | 52.63 | $14.52 B | — | 9.23% | -321.31% | $82.42 | $34.01 |
| 52. | BioCryst Pharmaceuticals, Inc. | 2.09% | — | -3.68 | $8.41 | 8.54 | $2.13 B | — | 107.2% | -328.82% | $11.31 | $6 |